HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Budget Reaffirms Commitment To OTCs, Reduces Supplement Programs

This article was originally published in The Tan Sheet

Executive Summary

FDA hopes to increase the number of over-the-counter drugs on the market as part of its long-term goal to provide consumers with safe, effective and affordable drugs, the agency states in its fiscal year 2007 budget request presentation

You may also be interested in...

DuPont Changing Labels For Antiseptic Products To Comply With FDA Warning

DuPont plans by the end of June to comply with FDA's warning to change the labels for its RelyOn antiseptic spray and hand-wipe products that include disease claims not approved in a pending monograph for OTC health care antiseptics or in the topical antifungal drug products monograph

FDA Will Close Labs As Spending Is Locked At 2006 Levels

FDA plans to close laboratories across the United States, according to a Dec. 6 e-mail message from the Office of Regulatory Affairs

CFSAN Targeting High-Profile Supplement Offenders To Maximize Value

In response to budgetary restraints, FDA's food center will focus enforcement actions on the most visible dietary supplement companies that violate advertising regulations, according to Center for Food Safety & Applied Nutrition Director Robert Brackett, PhD

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts